04 · 21 proprietary layers
Layer 7 of 21 · Tumour behaviour
Kinetix Growth dynamics and evolutionary trajectory.
Why it's needed
What does the available information suggest about tumour growth dynamics or evolution?
What it draws on
3 of 8 evidence domains.
What it produces
A structured description of supported dynamics-related evidence.
Why it's essential
Layer 7 of 21.
1 · What it does
What Kinetix does
Kinetix is intended to describe what the available information suggests about how the tumour is changing over time. It becomes meaningful mainly when there are repeated measurements, such as serial imaging or repeat molecular testing.
2 · Scientific question
The question it addresses
What does the available information suggest about tumour growth dynamics or evolution?
Intended function
Describe the layer's intended role in characterising dynamics when relevant longitudinal or modelled data exist.
3 · Data inputs and required context
What it draws on
- 01 Molecular & genomic
- 04 Imaging integration
- 06 Treatment exposure
Serial molecular or imaging data collected during the Twin journey, together with treatment history.
4 · Scientific basis
The science behind it
Scientific basis
Growth and evolutionary dynamics are generally studied from serial data — repeated imaging, serial circulating tumour DNA or repeated sequencing — often with mathematical models. From a single time-point, dynamics can only be inferred indirectly.
5 · Output and evidence sources
What it produces
Main output
A structured description of supported dynamics-related evidence.
Output type
- Computational inference. Estimated by analysis of available data rather than measured directly.
6 · Why it\u2019s essential
How it powers the Twin
Gives context to the longitudinal view, and to the comparisons made when the Twin is updated.
Report section
7 · Why it\u2019s needed
What it changes — for doctors, patients and researchers
Clinicians
A structured summary of change across time-points, with the data behind it.
Doctor & Clinical TeamPatients & caregivers
Explains why the Twin looks at change over time rather than a single result.
Patient & Caregiver8 · Dependencies and limitations
Limitations
- Depends on the frequency and quality of serial data; sparse data support only limited conclusions.
9 · Review and uncertainty
How the output is handled
Output status
An AI-assisted analytical output presented as structured findings for clinician review. It becomes part of a report only after the treating oncologist has reviewed and signed it.
How uncertainty is communicated
Dynamics are described only between available time-points, with the gaps between them made visible.
10 · Claim boundary
What this layer does not establish
It does not forecast how quickly the tumour will grow or when it will progress.
The treating oncologist owns every decision. Every Twin report is reviewed and signed by the treating oncologist, then taken to KPCIRC's Molecular Tumour Board.
KPCIRC sign-off process